January 21, 2022, Oncopeptides announced that the Company has contacted the US Food and Drug Administration and rescinded the October 22, 2021, letter requesting voluntary withdrawal of the NDA of Pepaxto® in the US.
Investors, financial analysts and media are invited to participate in a webcast with a Q&A session on January 24, 2022, at 09:00 (CET).
The event will be hosted by CEO, Jakob Lindberg and CMO, Klaas Bakker. The presentation will be held in English.
The webcast will be streamed via https://tv.streamfabriken.com/press-conference-jan-2022
SE: +46 856642651
UK: +44 3333000804
US: +1 6319131422
Read the press release